News | July 16, 2022
Indian pharmaceutical companies to grow by 6-7% in FY2023: ICRA
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
EVERSANA and Compai Pharma will provide medical and commercial resources to healthcare partners
Plant is part of the company's CAD $30 million capital investment in the site
MINYM can be safely used by patients above 9 years of age.
The appointments will add to the well-diversified experience that currently exists on the PPL board.
The combined company will be able to better serve both our global and regional customers with local production
This is the 142nd ANDA (including 8 tentative approvals received) out of Eugia Pharma Specialty Group (EPSG) facilities, manufacturing both oral and sterile specialty products.
The objective of this Phase 1 study is to determine the safety and tolerability of OLX10212 in patients with advanced AMD at multiple sites in the US.
_256_384.jpg){kind=logo}
Meets the growing need for US-based API solubility and bioavailability enhancement services
Subscribe To Our Newsletter & Stay Updated
